Skip to main content

Journal Club - May 5, 2022


Majeed Alosail presented the PACMAN-AMI Trial which was a double-blind, placebo-controlled, randomized clinical trial comparing the use of biweekly subcutaneous alirocumab to placebo, in addition to high-intensity statin therapy among patients undergoing percutaneous coronary intervention for acute myocardial infarction. Their primary outcome was the change in IVUS-derived percent atheroma volume from baseline to week 52. This trial was published in JAMA earlier this month and was presented at the recent ACC conference.

CCI is an inclusive centre with multidisciplinary membership for all cardiovascular investigators in BC